Korsten, Peter

[["dc.bibliographiccitation.firstpage","3529214"],["dc.bibliographiccitation.journal","Autoimmune Diseases"],["dc.bibliographiccitation.lastpage","3529214"],["dc.bibliographiccitation.volume","2017"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Niewold, Timothy B."],["dc.contributor.author","Zeisberg, Michael"],["dc.contributor.author","Utset, Tammy O."],["dc.contributor.author","Cho, Daniel"],["dc.contributor.author","Zachary, Lawrence S."],["dc.contributor.author","Sweiss, Nadera J."],["dc.contributor.author","Volkov, Suncica"],["dc.date.accessioned","2019-07-09T11:45:40Z"],["dc.date.available","2019-07-09T11:45:40Z"],["dc.date.issued","2017"],["dc.description.abstract","Objective: To investigate the role of whole blood viscosity in digital ulcer (DU) development in patients with diffuse and limited Systemic sclerosis. Methods: A convenience sample of patients with Systemic sclerosis (SSc) was selected from the adult Rheumatology clinic at the University of Chicago. The study group consisted of patients with SSc (with ulcers present, a history of ulcers, and no ulcers); the control group consisted of matched healthy Rheumatology clinic staff. WBV was measured using a scanning capillary viscometer at different shear rates (1-1000 1/s). Results: Whole blood viscosity as measured by a scanning capillary viscometer was increased in patients with SSc compared to healthy controls (p < 0.0001). Additionally, patients with present DU had significantly higher whole blood viscosity when compared to patients with a history of DU and patients with no history of DU (p < 0.0001). These findings were most pronounced at lower shear rates between 1 and 10 1/s. Conclusion: Whole blood viscosity might be a contributing factor in DU development in patients with SSc. Further studies with larger patient cohorts are required to fully evaluate how increased WBV contributes to the development of DU and whether the currently available treatment options improve the microcirculation by influencing WBV."],["dc.identifier.doi","10.1155/2017/3529214"],["dc.identifier.pmid","29318042"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15277"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59281"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-0422"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Increased Whole Blood Viscosity Is Associated with the Presence of Digital Ulcers in Systemic Sclerosis: Results from a Cross-Sectional Pilot Study."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","598"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Medical Case Reports"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Patschan, Daniel"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Behlau, Arne"],["dc.contributor.author","Vasko, Radovan"],["dc.contributor.author","Heeg, Malte H. J."],["dc.contributor.author","Sweiss, Nadera J."],["dc.contributor.author","Müller, Gerhard A."],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2019-07-09T11:53:25Z"],["dc.date.available","2019-07-09T11:53:25Z"],["dc.date.issued","2011"],["dc.description.abstract","Introduction Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition with various etiopathogeneses. Without therapy approximately 90% of all patients die from the disease. Case presentation We report the case of a 17-year-old Caucasian woman with widespread hematomas and headache. Due to hemolytic anemia, thrombocytopenia, and schistocytosis, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome was suspected and plasma exchange therapy was initiated immediately. Since her thrombocyte level did not increase during the first week of therapy, plasma treatment had to be intensified to a twice-daily schedule. Further diagnostics showed markedly reduced activities of both ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 - also known as von Willebrand factor-cleaving protease) and factor H. Test results for antibodies against both proteins were positive. While plasma exchange therapy was continued, rituximab was given once weekly for four consecutive weeks. After the last dose, thrombocytes and activities of ADAMTS-13 and factor H increased into the normal range. Our patient improved and was discharged from the hospital. Conclusions Since no clinical symptoms/laboratory findings indicated a malignant or specific autoimmune-mediated disorder, the diagnosis made was thrombotic thrombocytopenic purpura-hemolytic uremic syndrome due to idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency."],["dc.identifier.doi","10.1186/1752-1947-5-598"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7456"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60419"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/15282 but duplicate"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.holder","Patschan et al.; licensee BioMed Central Ltd."],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]